Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Conduit Pharmaceuticals Inc. - Common Stock
(NQ:
CDT
)
0.1067
+0.0076 (+7.67%)
Streaming Delayed Price
Updated: 1:00 PM EST, Nov 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Conduit Pharmaceuticals Inc. - Common Stock
Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders
November 21, 2024
Approval of composition of matter patent in key jurisdiction underscores the Company’s commitment to maximize future out-licensing value
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors
November 19, 2024
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline
November 04, 2024
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes
November 01, 2024
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Conduit Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
August 28, 2024
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders
August 12, 2024
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments
August 08, 2024
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Conduit Pharmaceuticals Receives Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
July 16, 2024
Composition of matter patent approval underscores the Company’s solid-form technology to maximize future value and ability to strengthen and broaden its intellectual property portfolio
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Conduit Pharmaceuticals to Join Russell 3000® Index
June 13, 2024
From
Conduit Pharmaceuticals
Via
GlobeNewswire
A Presidio Property Trust Major Investment To Be Part of Russell 2000®
May 29, 2024
From
Presidio Property Trust, Inc.
Via
GlobeNewswire
Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer
March 19, 2024
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Conduit Pharmaceuticals Announces Opening of Prime Laboratory Space in Europe’s Leading Life Sciences Hub
March 11, 2024
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Conduit Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
January 31, 2024
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Conduit Pharmaceuticals to Participate in the 14th Annual Jefferies London Healthcare Conference
November 02, 2023
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Conduit Pharmaceuticals Partners with ClinConnect on Cocrystal Development Program for AZD1656
October 11, 2023
Collaboration underscores Conduit’s mission to advance promising treatments by developing assets that have already completed Phase I trials
From
Conduit Pharmaceuticals
Via
GlobeNewswire
Presidio Property Trust Announces Closing of Merger of Its Sponsored SPAC Murphy Canyon Acquisition Corp Now Trading as Conduit Pharmaceuticals (Nasdaq: CDT and CDTTW)
October 06, 2023
From
Presidio Property Trust, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.